Beyond Air, Inc. (XAIR) Tops Q3 EPS by 4c

Go back to Beyond Air, Inc. (XAIR) Tops Q3 EPS by 4c

Beyond AirĀ® Reports Financial ResultsĀ for Third Quarter of Fiscal Year 2024

February 12, 2024 4:05 PM EST

Commercial demand for LungFit® PH increasing; manufacturing of upgraded devices is ramping up to meet growing demand

PMA supplement for the expansion of LungFit PH label to include cardiac surgery accepted for filing and under substantive review by the FDA

U.S. pilot trial of LungFit® PRO to treat viral community acquired pneumonia (VCAP) underway; trial will extend over two seasons; the pivotal study remains on track for Winter 2025/26

Phase 1 Study evaluating Beyond Cancers ultra-high concentration nitric oxide (UNO) in advanced, R/R... More